Flash Finance

Zota Health Care LImitedZOTACorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹1,409.30
MCap ₹4,881 Cr
Zota Health Care LImited — Stock analysis & AI research Zota Health Care LImited — Multibagger AI analysis Zota Health Care LImited — Seasonality — best & worst months Zota Health Care LImited — Technical indicators & charts Zota Health Care LImited — Technical setup — score, trend, support & resistance Zota Health Care LImited — Live exchange announcements
📈 MACD Bullish Crossover📈 Strong Trend Stocks (ADX > 25)📈 Bullish EMA Alignment📈 Stocks Above Anchored VWAP 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹174 Cr
Sales · Jun 2026
+66.9% YoY
₹-12 Cr
Operating Profit · Jun 2026
-389.9% YoY
-6.7%
OPM % · Jun 2026
-276.3% YoY
₹-44 Cr
Net Profit · Jun 2026
-213.9% YoY
₹-12.58
EPS · Jun 2026
-161.5% YoY

📝 Zota Health Care LImited — results explained

Quarter ended June 2026 (Q1 FY27)

Zota Health Care LImited reported revenue of ₹174 crore for the quarter ended June 2026 (Q1 FY27), up 66.9% from ₹104 crore in the same quarter last year, and up 6.5% sequentially over the March 2026 quarter.

The company reported a net loss of ₹44 crore, against a net loss of ₹14 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-12.58.

Operating profit stood at ₹-12 crore — an operating margin (OPM) of -6.7%, compared with 3.8% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Zota Health Care LImited posted revenue of ₹539 crore, a growth of 84.6% over FY25, with a net loss of ₹74 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹609 crore with a net loss of ₹104 crore.

Valuation snapshot

At the current price of ₹1,409.30, ZOTA has a market capitalisation of ₹4,881 crore.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 13th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 49.38%, foreign institutional investors (FIIs) 7.92%, domestic institutional investors (DIIs) 6.75%, public shareholders 35.96% of Zota Health Care LImited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹4,881 Cr
Current Price ?
₹1,409.3
P/E ?
N/A
Industry P/E ?
37.20
P/B ?
7.03
P/S ?
8.02
P/FCF ?
-24.78
Enterprise Value ?
₹5,151 Cr
EV/EBITDA ?
1,513.77
PEG ?
N/A
Earnings Yield ?
-1.8%
Dividend Yield ?
0.07%
Profitability & Returns
Sales (TTM) ?
₹609 Cr
OPM ?
0.6%
Profit after tax (TTM) ?
₹-104 Cr
EPS (TTM) ?
₹-30.01
ROCE ?
-8.0%
ROE ?
-15.0%
ROA ?
-9.2%
Growth
Sales — latest qtr ?
₹174 Cr
PAT — latest qtr ?
₹-44 Cr
YoY qtr sales growth ?
66.9%
YoY qtr profit growth ?
-213.9%
Sales growth (3y) ?
57%
Sales growth (5y) ?
38%
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹270 Cr
Debt to Equity ?
0.39
Interest Coverage ?
-3.8
Current Ratio ?
N/A
Ownership
Promoter holding ?
49.38%
Change in promoter holding ?
-8.04%
Pledged percentage ?
N/A
Market
Return 3 months ?
4.4%
Return 6 months ?
6.9%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 34373945475056677297104129143163174 +66.9% +6.5%
Operating Profit 01143-1-1-1-6-74609-12 -389.9% -228.9%
Other Income 1100000113122-32 +104.3% +168.1%
Interest 0111123321134556 +111.7% +27.0%
Depreciation 14355781011431519222728 +85.0% +2.8%
Profit Before Tax 0-3-3-1-3-10-12-13-18-58-13-14-26-26-44 -235.8% -67.9%
Net Profit 0-3-3-2-3-7-13-12-19-13-14-16-30-14-44 -213.9% -213.9%
EPS 0.10-1.05-1.13-0.64-1.14-2.68-4.79-4.41-6.78-4.50-4.81-5.20-8.73-4.09-12.58 -161.5% -207.6%
OPM % 0.4% 2.7% 3.3% 8.9% 6.4% -2.0% -1.8% -1.5% -8.3% -7.3% 3.8% 4.7% 0.0% 5.5% -6.7% -276.3% -221.8%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹292 Cr ₹539 Cr ₹609 Cr +84.6%
Operating Profit ₹-15 Cr ₹19 Cr ₹3 Cr +225.8%
OPM % -5.17% 3.53% 0.56% +168.3%
NPM % -19.52% -13.73% -17.08% +29.7%
Other Income ₹5 Cr ₹2 Cr ₹3 Cr -63.2%
Depreciation ₹72 Cr ₹83 Cr ₹96 Cr +15.0%
Interest ₹19 Cr ₹17 Cr ₹20 Cr -9.5%
EBIT ₹-87 Cr ₹-64 Cr ₹-92 Cr +26.7%
PBT ₹-101 Cr ₹-79 Cr ₹-110 Cr +21.5%
Tax — — ₹0 Cr —
Net Profit ₹-57 Cr ₹-74 Cr ₹-104 Cr -29.8%
EPS ₹-20.48 ₹-22.83 ₹-30.60 -11.5%
Material Cost — — ₹86 Cr —
Employee Cost — — ₹61 Cr —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 25262935 +20.7%
Reserves 5564195659 +237.9%
Borrowings 4595140270 +92.9%
Other Liabilities 334376167 +119.7%
Total Liabilities 1582284391,131 +157.6%
Fixed Assets 62103185383 +107.0%
CWIP 3562 -66.7%
Investments 8554264 +388.9%
Other Assets 85116193483 +150.3%
Total Assets 1582284391,131 +157.6%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -2-6-50-84 -68.0%
Cash from Investing Activity 15-13-92-314 -241.3%
Cash from Financing Activity -1419145490 +237.9%
Net Cash Flow -1-0392 +2966.7%
Free Cash Flow -13-23-96-197 -105.2%
CFO/OP 2%-59%811%-394% -148.6%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 73555150 -2.0%
Inventory Days 183201277329 +18.8%
Days Payable 116126111178 +60.4%
Cash Conversion Cycle 140131217200 -7.8%
Working Capital Days 1117510084 -16.0%
ROCE % -2%-7%-17%-8% +52.9%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 57.42%55.81%50.64%49.38%49.38% +0.0%
FIIs 3.82%3.49%8.09%8.21%7.92% -3.5%
DIIs 4.25%4.95%7.22%6.40%6.75% +5.5%
Public 34.52%35.75%34.06%36.00%35.96% -0.1%
No. of Shareholders 10,35411,85513,18514,00514,678 +4.8%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Zota Health Care LImited's revenue in Q1 FY27?
Zota Health Care LImited reported revenue of ₹174 crore for the quarter ended June 2026 (Q1 FY27), up 66.9% from ₹104 crore in the same quarter last year, and up 6.5% sequentially over the March 2026 quarter.
What was Zota Health Care LImited's net profit in Q1 FY27?
The company reported a net loss of ₹44 crore, against a net loss of ₹14 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-12.58.
What is ZOTA's market capitalisation and P/E ratio?
At the current price of ₹1,409.30, ZOTA has a market capitalisation of ₹4,881 crore.
Who owns Zota Health Care LImited? (shareholding pattern)
As of Jun 2026, promoters held 49.38%, foreign institutional investors (FIIs) 7.92%, domestic institutional investors (DIIs) 6.75%, public shareholders 35.96% of Zota Health Care LImited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI